Genome-scale CRISPR Screens Reveal DNA Repair Dependencies that Sensitize Hepatocellular Carcinoma to Oxaliplatin
Hepatic arterial infusion chemotherapy with FOLFOX regimen which contains oxaliplatin has been demonstrated to provide survival benefit, but chemoresistance substantially reduces response rates and clinical efficacy. To systemati-cally identify strategies that increase oxaliplatin sensitivity, we performed genome-scale negative-selection CRISPR-Cas9 screens in two hepatocellular carcinoma cell lines. DNA damage response pathways emerged as conserved sensitizers to oxaliplatin.